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Summary: The case presented here illustrates a 75 year old female patient who underwent surgical resection of a right 
adrenal mass of uncertain nature. The ﬁ  nal histological diagnosis was consistent with leiomyosarcoma arising from the 
adrenal anatomic site.
Primary leiomyosarcoma of the adrenal gland is a very rare malignant mesenchymal neoplasm: to our knowledge, this is 
only the twelfth case reported in literature.
We describe the clinical course and a brief review of clinical and histological features, biologic behaviour, diagnostic 
approaches and therapeutic strategies.
Case Report
A 75-year-old white female was admitted to the Department of Urology of our hospital following the 
ultrasound ﬁ  nding of a right adrenal mass of uncertain nature. Her medical history was unremarkable, 
except for long-term essential arterial hypertension. For a month prior to hospitalization the patient had 
complained of persistent and progressive epigastric and right loin pain. Physical examination showed 
only mild abdominal discomfort at palpation. No enlarged lymph nodes were present. Laboratory tests 
detected no abnormalities. Urinary levels of vanilmandelic acid, catecolamines and plasmatic level of 
aldosterone were normal.
Chest radiograph and electrocardiogram revealed no pathological ﬁ  ndings. Upper gastrointestinal 
endoscopy detected oesophageal hiatal hernia with reﬂ  ux oesophagitis, and total-body CT conﬁ  rmed 
the presence of a right adrenal mass of about 5 × 4 cm, suspected to be an adrenal carcinoma, so radical 
surgery was planned and performed with the resection of a roundish formation from the adrenal ana-
tomic site. Normal adrenal gland was not visible (Fig. 1).
Three days after surgery the patient developed a pulmonary embolism: an inferior vena cava throm-
bosis was identiﬁ  ed by angio-CT scan. Pulmonary embolism was identiﬁ  ed by angio-CT scan, too. 
Moreover, an unexplained progressive drop of hemoglobin concentration down to 7.7 g/dl, requiring 
infusion of two units of packed red cells, was observed. The patient was transferred to our Intensive 
Care Unit, where she received routine treatment for pulmonary embolism including anticoagulant 
therapy ﬁ  rst with intravenous heparin and then with warfarin.
The clinical course was satisfactory, and subsequent Doppler-ultrasonography conﬁ  rmed the return 
to normal of venous ﬂ  ow through inferior vena cava. The patient, clinically stable with a good cardio-
respiratory compensation, was discharged on postoperative day 18; continuation of anticoagulant 
therapy and physical rehabilitation were recommended. No oncological treatment was provided after 
surgery, and no evidence of recurrent disease was observed one year later.
Gross pathological examination of the resected tissue showed a roundish, ﬁ  brous neoformation of 
8 × 4 × 5 cm. A thrombus was detected inside the adrenal vein; this thrombus was not visible on CT 
performed before surgery. On sectioning of the mass, no adrenal structure was recognizable. Resection 
margins were free of disease. Histologically, tissue sections showed a neoplasm consisting of elongated 
cells with eosinophilic cytoplasma and elongated nuclei with rounded ends, small nucleolus with moderate 
polymorphism; the cells are arranged in fascicles; on average, 16/50 HPF mitoses were observed. No 
necrotic areas were detected (Fig. 1).354
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Neoplastic cells were strongly and diffusely 
positive immunohistochemical staining for desmin, 
SMA(1A4)(-Smooth Muscle Actin (1A4) Rimary 
Antibody) and actin (HHF3 Muscle-Specific 
Actin -HHF35- Primary Antibody 5-) (Fig. 2); 
immunohistochemical staining for CD34 and 
CD117 was negative. Ki-67 nuclear antigen 
(monoclonal MIB1 Antibody) was 20%. The 
ﬁ  nal histological diagnosis was consistent with 
leiomyosarcoma (UICC: pT2b/G2) arising from 
the adrenal anatomic site and substituting adrenal 
gland. An adrenal origin was thus deemed very 
likely.1,2
Intra-abdominal soft-tissue tumours represent 
only 0,1%-0,2% of all adult malignancies; among 
them leiomyosarcoma is the most common 
histological subtype, accounting for approxi-
mately 25%–30% of cases. However, primary 
leiomyosarcoma of the adrenal gland is a very rare 
malignant mesenchymal tumour: to our knowledge, 
this is only the twelwfth case reported in 
literature.
3,4,5,6,7,8,9,10,11,12
The aetiology of these neoplasms is unclear. A 
growing incidence of smooth muscle tumours in 
HIV and Epstein-Barr virus positive patients has 
been reported, but nothing certain is known about 
the pathogenetic involvement of these viruses.
13 
Despite the slow growth and late metastasis, leio-
myosarcoma still carries a poor prognosis. The 
tumour may grow to a large size before directly 
invading adjacent structures; systemic spread 
occurs late, but there is a high incidence of local 
recurrence.
At present, the prognosis for leiomyosarcoma 
patients is not predictable. Survival depends on 
tumour size, location, feasibility of complete 
resection
14 and morphologic grading (presence 
of mitotic activity, necrotic areas, nuclear 
atypia).
15,16 The morphology-based grading sys-
tem alone makes it difﬁ  cult to predict outcome, 
although in some studies tumour size and histo-
logical grade have correlated with biologic 
behaviour. In fact, little is known about the 
mechanisms underlying the development of 
Figure 1. Gross appearance of the roundish, ﬁ  brous neoplasia. 
Insert: neoplasia with fascicular growth pattern (E.E. 40×).355
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aggressive tumour behaviour, and about the 
molecular genetic changes associated with 
clinical outcome. Chromosomal aberrations may 
contribute to morphological changes in soft-tissue 
leiomyosarcomas,
17,18 as these alterations of gene 
expression appear to be correlated with the 
tumour’s clinical behaviour and histological 
grade. The striking dissimilarities in the gene 
expression patterns of leiomyosarcomas of 
varying differentiation status and clinical aggres-
siveness seem to suggest that several and differ-
ent genetic abnormalities are responsible for the 
genesis and progression of this tumour.
19 For 
instance, 13q14-q21 loss and 5p14-pter gain at 
diagnosis could be used to identify patients with 
leiomyosarcoma who are likely to have a shorter 
survival and who might benefit from early 
treatment intensification. Analysis of the 
RB-1 genes and proteins in the Rb-cyclinD 
pathway has revealed frequent abnormalities in 
leiomyosarcomas.
Because of the prolonged time interval separat-
ing the diagnosis of the primary tumour and the 
involvement of distant sites, an accurate and early 
diagnosis of these neoplasms must be made. Indeed, 
improved diagnostic approaches are enabling the 
early diagnosis and surgical treatment of an increas-
ing number of cases. Radical surgical resection 
remains the only proven therapeutic modality that 
prolongs the survival in patients with leiomyosar-
coma.
15,20 Histological grade often correlates with 
biological behaviour and with prognosis. The prin-
cipal sites of metastasis are lungs and liver; regional 
lymph node metastasis are rare.
Postoperative adjuvant radiation therapy is 
recommended for the treatment of locally advanced 
malignancy.
21 The efﬁ  cacy of chemotherapy is 
poorly deﬁ  ned and very limited; pre-operatively it 
can be performed in cases of inoperable tumours, 
whereas in the post-operative setting it may be 
suggested for incompletely resected or metastatic 
tumours. In patients with locally advanced or 
metastatic disease any one of the many schemes 
containing an anthracycline and/or ifosfamide may 
be considered the standard.
15 Few chemotherapeu-
tic agents are active as second-line treatment. 
Gemcitabine, taxans and others are considered 
quite ineffective, although responses to these 
agents have been reported in rare cases.
22,23
Conclusively, complete surgical resection fol-
lowed by a combination of radiotherapy and 
chemotherapy may constitute the optimal treatment 
for advanced leiomyosarcoma to ensure long-term 
survival, even if recurrences are frequent.
15,24 In 
our case, the tumour had completely replaced the 
right adrenal gland but no other structure appeared 
to be inﬁ  ltrated.
Treatment was therefore limited to surgical 
resection with no oncological treatment provided 
after surgery, and no evidence of recurrent disease 
was observed one year later.
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Figure 2. (A) Positive Desmin immunostaining (20x); (B) Positive 
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